Published in final edited form as:

Congenit Heart Dis. 2018 January ; 13(1): 140–146. doi:10.1111/chd.12544.

Comparison of Valvar and Right Ventricular Function Following Transcatheter and Surgical Pulmonary Valve Replacement

Wendy F Li, BS¹, Heidi Pollard, RDCS², Mohsen Karimi, MD³, Jeremy D Asnes, MD¹, William E Hellenbrand, MD¹, Veronika Northrup, MPH, and Constance G Weismann, MD^{1,5}

¹Department of Pediatrics, Division of Pediatric Cardiology, Yale University School of Medicine

²Pediatric Echocardiography Laboratory, Yale New Haven Children's Hospital

³Department of Surgery, Division of Pediatric Cardiothoracic Surgery, Yale University School of Medicine

⁴Yale Center for Analytical Sciences

⁵Pediatric Heart Center, Skåne Universitetssjukhus, Lund, Sweden

Abstract

Objective—Trans-catheter (TC) pulmonary valve replacement (PVR) has become common practice for patients with right ventricular outflow tract obstruction (RVOTO) and/or pulmonic insufficiency (PI). Our aim was to compare PVR and right ventricular (RV) function of patients who received TC vs surgical PVR.

Design—Retrospective review of echocardiograms obtained at three time points: before, immediately after PVR, and most recent.

Patients—62 patients (median age 19 years, median follow-up 25 months) following TC (N=32) or surgical (N=30) PVR at Yale-New Haven Hospital were included.

Outcome Measures—Pulmonary valve and right ventricular function immediately before, immediately after, and most recently after PVR.

Results—At baseline, the TC group had predominant RVOTO (74% vs. 10%, $p<0.001$), and moderate-severe PI was less common (61% vs. 100%, $p<0.001$). Immediate post-procedural PVR function was good throughout. At last follow-up, the TC group had preserved valve function, but the surgical group did not (moderate RVOTO: 6% vs. 41%, $p<0.001$; >mild PI: 0% vs 24%,

Corresponding Author: Constance G. Weismann, M.D., Pediatric Heart Center, Skåne Universitetssjukhus, Lasarettgatan 48, 22241 Lund, Sweden, Phone +46-72-876-2481, constance.weismann@gmail.com.

Conflicts of Interest: WE Hellenbrand is proctor for Medtronic

IRB approval at Yale University: #1207010587; date of first approval 7/27/2012

Author Contributions

Concept/Design—CW

Data collection—WL, HP, CW

Data analysis/interpretation—CW, VN, WL, HP

Drafting article—CW, WL

Critical revision of article— all

Approval of article— all

Statistics— VN, CW

p=0.003). Patients younger than 17 years at surgical PVR had the highest risk of developing PVR dysfunction, while PVR function in follow-up was similar in adults. Looking at RV size and function, both groups had a decline in RV size following PVR. However, while RV function remained stable in the TC group, there was a transient postoperative decline in the surgical group.

Conclusion—TC PVR in patients age <17 years is associated with better PVR function in follow-up compared to surgical valves. There was a transient decline in RV function following surgical but not TC PVR. TC PVR should therefore be the first choice in children who are considered for PVR, whenever possible.

Keywords

Melody valve; transcatheter; surgical; pulmonary valve replacement; right ventricular function; echocardiography

1. Introduction

Chronic pulmonary insufficiency (PI) and/or right ventricular outflow tract obstruction (RVOTO) are common among patients with congenital heart disease. They often lead to progressive right ventricular (RV) dilation and dysfunction, and sometimes associated left ventricular diastolic and systolic dysfunction. These are well-known risk factors for arrhythmias, sudden death, and heart failure.(1–4) Thus, adequate timing of pulmonary valve replacement (PVR) is critical in order to prevent such complications. Prior to approval of the first trans-catheter (TC) PVR Melody valve (Medtronic Inc., Minneapolis, MN) by the United States Food and Drug Administration (FDA) in 2010, many of these patients required repeated surgical PVR throughout a lifetime, with an associated increasing risk of perioperative complications. Over the last 7 years, TC PVR has become common practice for patients with RVOTO and/or PI as a less invasive alternative to traditional surgical PVR. The Melody valve, as the first FDA approved TC PVR, has been studied most extensively. It has been shown to be safe and effective with excellent short- and intermediate-term outcomes.(5–8) Some cardiologists therefore advocate for an earlier PVR when using a TC valve compared to surgical PVR.(9)

To date, there is little data comparing outcomes in patients who receive TC vs. surgical PVR. The aim of this study was to compare PVR and RV function of patients who received TC Melody valves to those who underwent surgical PVR before, shortly following PVR, and at the time of last follow-up.

2. Methods

This is a retrospective cohort study of congenital heart disease patients who underwent Melody valve (group TC) or surgical (group S) PVR at Yale New Haven Children's hospital between January 2011 and June 2014.

Exclusion criteria were lack of follow-up echocardiogram >180 days following PVR. We recorded patients' original cardiac anatomy, prior surgeries, and clinical characteristics such as age, age at valve replacement, and body surface area. Right ventricular outflow tract

(RVOT) physiology prior to PVR was categorized as follows: 1. at least moderate RVOTO, at most mild PI, 2. moderate or severe PI, at most mild RVOTO, 3. at least moderate RVOTO and moderate or severe PI. Echocardiograms from three different time points (last study prior to PVR, first study after PVR, and last available follow-up) were analyzed (see 2.1).

PVR dysfunction as the primary outcome was defined as the presence of at least moderate graft PS and/or PI.

2.1. Echocardiograms

Echocardiograms were performed by experienced pediatric echocardiographers according to the pediatric guidelines of the American Society of Echocardiography.(10) Philips IE33 (Philips Medical Systems, Andover, MA), and Siemens Sequoia SC2000 (Siemens Medical Solutions USA, Mountain View, CA) were used, and probe frequency was selected according to patient size. Measurements were performed offline (Lumedx, Oakland, CA) and averaged over three cardiac cycles. All measurements were performed by at least one of three investigators (W.L., H.P., C.W.).

RVOTO was graded according to the American Society of Echocardiography (ASE) guidelines for pulmonic stenosis (maximum instantaneous gradient <36mmHg for mild, 36–64 mmHg for moderate, >64 mmHg for severe stenosis). (11) Pulmonary insufficiency was graded as none/trivial, mild, moderate/severe. Severity of tricuspid regurgitation (TR), and estimated right ventricular systolic pressure based on TR jet velocity were documented as well.

Parameters characterizing right heart structure (right atrial major and minor dimensions, right atrial end-systolic area, right ventricular dimension at the base and mid-ventricular level, RV end-diastolic and end-systolic areas, RVOT dimensions proximal and distal, RV wall thickness) and function (tricuspid annular plane systolic excursion [TAPSE], pulse wave tissue Doppler [TDI] derived peak systolic [S'], early [E'] and late [A'] diastolic velocities at the lateral tricuspid valve annulus, and fractional area change) were determined according to the American Society of Echocardiography (ASE) guidelines.(12)

2.2. Statistics

Continuous variables are expressed as median (range), categorical ones as numbers (percent). Unadjusted between-group comparisons of continuous variables were done using Analysis of variance (ANOVA) and Wilcoxon Rank-Sum test for normal and non-normal distributions respectively. Chi-square test or Fisher exact test were used as appropriate to compare categorical variables between groups. Receiver operating characteristics (ROC) curves were created. Multiple logistic regression modeling was used to determine risk factors for developing PVR dysfunction. For analysis of right heart size and function we used mixed effects linear regression approach to control for effects of preoperative RVOT physiology (PS, PI, or mixed PS/PI), age at procedure and BSA, as well as the subject effect (using a random intercept). The set significance level was $p < 0.05$. Statistical analysis was performed using Statistical Package for Social Sciences, version 21 (IBM SPSS, Chicago, IL).

3. Results

3.1. Baseline clinical characteristics

We identified 76 patients who had undergone surgical or TC PVR between January 2011 and June 2014. Fourteen patients were excluded because the follow-up period was <180 days (4 surgical, 10 TC). The cohort had a median age of 19.2 (range 4.7 – 63.1) years and was divided into group TC (n=32) and group S (surgical PVR; n=30). There was no significant difference between groups in age, gender, body surface area, or length of follow-up (table 1). In the TC group, the most frequent underlying cardiac diagnoses were tetralogy of Fallot (TOF) with or without pulmonary atresia (24/32 [75%]), and the most common prior interventions were bioprosthetic valve or homograft (23/32 [72%]) though 8 (25%) patients had TC placed following a transannular patch. In the surgical group S, TOF spectrum (16/30 [53%]), valvar pulmonic stenosis or atresia (13/30 [43%]) were the most common underlying lesions, and transannular patch the most frequent prior surgery (23/30 [77%]).

The RVOT physiology at baseline differed between the two groups as well, in that the majority of group S had PI without significant RVOT obstruction, while the picture was rather mixed in group TC (table 1,2).

3.2. Right ventricular outflow tract physiology

At the initial post-procedural echocardiogram group TC had a slightly higher peak gradient across the RVOT, but there was no significant PI in either group (table 2). At most recent follow-up, however, group TC had stable valve function without significant insufficiency or stenosis (2/32 [6%] with moderate stenosis). By contrast, patients in group S commonly had significant RVOT obstruction (12/30 [41%]) and/or PI (7/30 [24%]; table 2). Three patients in group S received subsequent TC PVR between 18.2 and 46.4 months following surgical PVR. All of those patients were < 17 years old at the time of PVR.

3.3. Effect of age at PVR on surgical PVR dysfunction

There was a strong effect of age at surgical PVR on the occurrence of significant PVR dysfunction (area under the curve (AUC) 0.86 [95% confidence interval 0.72–0.99, p=0.001]). Age <17 years had an 81% sensitivity and 79% specificity for having valve dysfunction in follow-up. In a multiple logistic regression model, only age at intervention <17 years (p=0.02; adjusted OR 14.8, 95% CI 1.6–139), but not length of follow-up (p=0.79) or type of surgical valve placed (p=0.60) were associated with surgical PVR dysfunction.

3.4. Groups TC vs S - age effect on PVR function

For patients <17 years of age at the time of PVR, the TC group had significantly better valve function in follow-up compared to group S (table 3). For patients age 17 or more, there was no significant difference between groups TC and S. In a multiple logistic regression model, length of follow-up was not significantly associated with higher risk for valve dysfunction in either group.

3.5. Right heart structure and function

Lastly, we evaluated the effect of TC vs S PVR on right heart size and function (table 4). Both groups had a significant decrease in right atrial and RV size following PVR, whereas RVOT dimensions and RV free wall thickness showed no significant change. RV systolic function assessed by quantitative echocardiographic measures remained stable following TC PVR. However, in group S there was a significant decline in RV function immediately following PVR (table 4) that only partially recovered at the time of last follow-up.

4. Discussion

This is the first published study on patients with TC vs surgical PVR that compares both PVR and right heart function in follow-up. We demonstrate strikingly better valve function of TC Melody valves vs. bioprosthetic surgical valves in children and adolescents <17 years of age at the time of intervention. Patients age 17 years or older had comparable valve function in follow-up. Further, the transient decline in RV function after surgical PVR is not seen following TC PVR.

4.1. Indications for PVR

Timing of PVR in pediatric patients continues to be controversial given the associated added risk of additional cardiac surgical procedures in a life time. Prior studies have suggested that an aggressive approach to PVR (end diastolic volume <150 ml/m²) leads to normalization of RV volumes, and improvement in biventricular function, and submaximal exercise capacity. (13) The authors showed that normalization of ventilatory response to carbon dioxide production, a parameter that has been shown to predict outcome in TOF, is most likely to occur when surgery is performed below age <17.5 years. (13, 14)

4.2. Data on Surgical PVR

Data on surgical PVR durability, however, varies widely from 50–96% at 10 years. (15–17) A large study of 505 patients pediatric and young adult patients has shown that homografts may be superior to xenografts with a mean time to reoperation of 16 compared to 10.3 years. (18) The effect of age on PVR longevity has also been analyzed by several groups, suggesting that younger age at PVR predicts shorter graft longevity. (19–22) Earlier PVR dysfunction appears particularly noticeable in children <13–18 years of age. (17, 20, 21) These reports are consistent with our data on surgical PVR showing that children <17 years of age at the time of PVR were at high risk for early valve dysfunction. Due to the rapid valve degeneration in some of our young patients with surgical PVR we believe that somatic growth alone cannot explain this phenomenon. We speculate that other e.g. immunologic factors may play a role. (23, 24) Whatever the cause of early valve degeneration in children and adolescents is – we have to acknowledge that there is a fine balance between preserving RV function and limiting the number of surgeries in a lifetime.

4.3. Data on TC PVR

Over the last decade TC PVR has been used increasingly. It has been shown in a single center study of 51 patients (including 26 younger than 16 years of age) that younger age at the time of TC PVR is associated with incremental improvements in RV size, function and

maximum oxygen consumption. (9) Procedural and mid-term results with up to seven years follow-up have been excellent. (8, 9, 25) As experience with TC PVR is growing, some centers – including ours - have been successfully placing TC PVR in native outflow tracts as well. (26) TC TPV replacement can also be performed in children <30 kg with good procedural and early hemodynamic results in the majority of patients. (27) In small children (< 15 kg) who are not suitable for a TC approach, the Melody valve has been placed via the periventricular route with good mid-term results (personal experience).

Given the previously published positive effect of younger age at the time of TC PVR on RV size, function and maximum oxygen consumption (9) and our data showing that TC PVR longevity is excellent and comparable to adult patients, we suggest that TC PVR should in fact be considered first choice in children and adolescents, including select patients with a 'native' RVOT or a transannular patch.

4.4. Right heart remodeling following PVR

Right atrial and right ventricular size decreased in both groups following PVR. However, there was a differential effect on quantitative parameters of RV systolic function – while function was preserved in group TC, there was a transient decline in group S that only partially recovered in follow-up. This effect is likely related to cardiopulmonary bypass (CPB) as a decline in longitudinal right ventricular function has been described previously. (28) While our findings should be validated in a larger cohort and validated by MRI, they are further evidence supporting TC PVR when feasible.

4.5. Limitations

This study's main limitation is that it is a retrospective observational echocardiography based study without concomitant MRI imaging. As the duration of follow-up is limited, we plan to revisit the data in a few years to assess long-term results.

4.6. Conclusion

We conclude that TC Melody valve placement in patients <17 years of age is associated with better pulmonary valve function in mid-term follow-up when compared to surgical PVR. In adult patients, however, there was a low incidence of PVR dysfunction in both groups. The transient decline in RV function seen following surgical PVR was not observed following TC PVR. We propose that TC Melody PVR should therefore be the first choice for children and adolescents who are considered for PVR. This should include patients who have undergone a transannular patch or who have a 'native' outflow if their RVOT is considered favorable on a preprocedural MRI.

Acknowledgments

Grant support: Wendy Li's contribution was supported by the National Institutes of Health [grant number T35HL007649].

Glossary of Abbreviations

ANOVA Analysis of variance

CPB	Cardiopulmonary bypass
EF	Ejection fraction
MRI	Magnetic resonance imaging
PI	Pulmonic insufficiency
PS	Pulmonary valve stenosis
PVR	Pulmonary valve replacement
ROC	Receiver operating characteristics
RVOTO	Right ventricular outflow tract obstruction
S	Surgical
TAPSE	Tricuspid annular plane systolic excursion
TC	Transcatheter
TDI	Tissue Doppler imaging
TOF	Tetralogy of Fallot

References

1. Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. *Lancet*. 2000 Sep 16; 356(9234):975–81. [PubMed: 11041398]
2. Ghai A, Silversides C, Harris L, Webb GD, Siu SC, Therrien J. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. *J Am Coll Cardiol*. 2002 Nov 6; 40(9):1675–80. [PubMed: 12427422]
3. Knauth AL, Gauvreau K, Powell AJ, Landzberg MJ, Walsh EP, Lock JE, et al. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. *Heart*. 2008 Feb; 94(2):211–6. [PubMed: 17135219]
4. Nollert G, Fischlein T, Bouterwek S, Bohmer C, Klinner W, Reichart B. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. *J Am Coll Cardiol*. 1997 Nov 1; 30(5):1374–83. [PubMed: 9350942]
5. Lurz P, Coats L, Khambadkone S, Nordmeyer J, Boudjemline Y, Schievano S, et al. Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome. *Circulation*. 2008 Apr 15; 117(15):1964–72. [PubMed: 18391109]
6. Butera G, Milanesi O, Spadoni I, Piazza L, Donti A, Ricci C, et al. Melody transcatheter pulmonary valve implantation. Results from the registry of the Italian Society of Pediatric Cardiology. *Catheter Cardiovasc Interv*. 2013 Feb; 81(2):310–6. [PubMed: 22718682]
7. McElhinney DB, Cheatham JP, Jones TK, Lock JE, Vincent JA, Zahn EM, et al. Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody Valve Trial. *Circ Cardiovasc Interv*. 2011 Dec 1; 4(6):602–14. [PubMed: 22075927]
8. Cheatham JP, Hellenbrand WE, Zahn EM, Jones TK, Berman DP, Vincent JA, et al. Clinical and Hemodynamic Outcomes up to 7 Years After Transcatheter Pulmonary Valve Replacement in the US Melody Valve Investigational Device Exemption Trial. *Circulation*. 2015 Jun 2; 131(22):1960–70. [PubMed: 25944758]

9. Borik S, Crean A, Horlick E, Osten M, Lee KJ, Chaturvedi R, et al. Percutaneous pulmonary valve implantation: 5 years of follow-up: does age influence outcomes? *Circ Cardiovasc Interv.* 2015 Feb; 8(2):e001745. [PubMed: 25652317]
10. Valente AM, Cook S, Festa P, Ko HH, Krishnamurthy R, Taylor AM, et al. Multimodality imaging guidelines for patients with repaired tetralogy of fallot: a report from the American Society of Echocardiography: developed in collaboration with the Society for Cardiovascular Magnetic Resonance and the Society for Pediatric Radiology. *J Am Soc Echocardiogr.* 2014 Feb; 27(2):111–41. [PubMed: 24468055]
11. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *J Am Soc Echocardiogr.* 2009 Jan; 22(1):1–23. quiz 101–2. [PubMed: 19130998]
12. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr.* 2010 Jul; 23(7):685–713. quiz 86–8. [PubMed: 20620859]
13. Frigiola A, Tsang V, Bull C, Coats L, Khambadkone S, Derrick G, et al. Biventricular response after pulmonary valve replacement for right ventricular outflow tract dysfunction: is age a predictor of outcome? *Circulation.* 2008 Sep 30; 118(14 Suppl):S182–90. [PubMed: 18824753]
14. Giardini A, Specchia S, Tacy TA, Coutsoumbas G, Gargiulo G, Donti A, et al. Usefulness of cardiopulmonary exercise to predict long-term prognosis in adults with repaired tetralogy of Fallot. *Am J Cardiol.* 2007 May 15; 99(10):1462–7. [PubMed: 17493481]
15. Lee C, Kim YM, Lee CH, Kwak JG, Park CS, Song JY, et al. Outcomes of pulmonary valve replacement in 170 patients with chronic pulmonary regurgitation after relief of right ventricular outflow tract obstruction: implications for optimal timing of pulmonary valve replacement. *J Am Coll Cardiol.* 2012 Sep 11; 60(11):1005–14. [PubMed: 22921969]
16. Babu-Narayan SV, Diller GP, Gheta RR, Bastin AJ, Karonis T, Li W, et al. Clinical outcomes of surgical pulmonary valve replacement after repair of tetralogy of Fallot and potential prognostic value of preoperative cardiopulmonary exercise testing. *Circulation.* 2014 Jan 7; 129(1):18–27. [PubMed: 24146254]
17. Batlivala SP, Emani S, Mayer JE, McElhinney DB. Pulmonary valve replacement function in adolescents: a comparison of bioprosthetic valves and homograft conduits. *Ann Thorac Surg.* 2012 Jun; 93(6):2007–16. [PubMed: 22560964]
18. Homann M, Haehnel JC, Mendler N, Paek SU, Holper K, Meisner H, et al. Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts. *Eur J Cardiothorac Surg.* 2000 Jun; 17(6):624–30. [PubMed: 10856850]
19. Tweddell JS, Pelech AN, Frommelt PC, Mussatto KA, Wyman JD, Fedderly RT, et al. Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. *Circulation.* 2000 Nov 7; 102(19 Suppl 3):III130–5. [PubMed: 11082375]
20. Bokma JP, Winter MM, Oosterhof T, Vliegen HW, van Dijk AP, Hazekamp MG, et al. Individualised prediction of pulmonary homograft durability in tetralogy of Fallot. *Heart.* 2015 Nov; 101(21):1717–23. [PubMed: 26175476]
21. McKenzie ED, Khan MS, Dietzman TW, Guzman-Pruneda FA, Samayoa AX, Liou A, et al. Surgical pulmonary valve replacement: a benchmark for outcomes comparisons. *J Thorac Cardiovasc Surg.* 2014 Oct; 148(4):1450–3. [PubMed: 24703628]
22. Nomoto R, Sleeper LA, Borisuk MJ, Bergerson L, Pigula FA, Emani S, et al. Outcome and performance of bioprosthetic pulmonary valve replacement in patients with congenital heart disease. *J Thorac Cardiovasc Surg.* 2016 Nov; 152(5):1333–42. e3. [PubMed: 27637422]
23. Barone A, Benktander J, Teneberg S, Breimer ME. Characterization of acid and non-acid glycosphingolipids of porcine heart valve cusps as potential immune targets in biological heart valve grafts. *Xenotransplantation.* 2014 Nov-Dec; 21(6):510–22. [PubMed: 25041314]
24. Reuven EM, Leviatan Ben-Arye S, Marshanski T, Breimer ME, Yu H, Fellah-Hebia I, et al. Characterization of immunogenic Neu5Gc in bioprosthetic heart valves. *Xenotransplantation.* 2016 Sep; 23(5):381–92. [PubMed: 27610947]

25. Kenny D, Hijazi ZM, Kar S, Rhodes J, Mullen M, Makkar R, et al. Percutaneous implantation of the Edwards SAPIEN transcatheter heart valve for conduit failure in the pulmonary position: early phase 1 results from an international multicenter clinical trial. *J Am Coll Cardiol*. 2011 Nov 15; 58(21):2248–56. [PubMed: 22078433]
26. Meadows JJ, Moore PM, Berman DP, Cheatham JP, Cheatham SL, Porras D, et al. Use and performance of the Melody Transcatheter Pulmonary Valve in native and postsurgical, nonconduit right ventricular outflow tracts. *Circ Cardiovasc Interv*. 2014 Jun; 7(3):374–80. [PubMed: 24867892]
27. Berman DP, McElhinney DB, Vincent JA, Hellenbrand WE, Zahn EM. Feasibility and short-term outcomes of percutaneous transcatheter pulmonary valve replacement in small (<30 kg) children with dysfunctional right ventricular outflow tract conduits. *Circ Cardiovasc Interv*. 2014 Apr; 7(2): 142–8. [PubMed: 24569596]
28. Pauliks LB, Valdes-Cruz LM, Perryman R, Scholl FG. Right ventricular wall-motion changes after infant open heart surgery-a tissue Doppler study. *Echocardiography*. 2014 Feb; 31(2):209–17. [PubMed: 24103038]

Table 1
Baseline characteristics for patients who underwent transcatheter (TC) Melody versus surgical pulmonary valve replacement (PVR).

	Transcatheter PVR (n=32)		Surgical PVR (n=30)	p
Age at PVR	22.1 (4.7–55.3)		16.5 (5.1–63.1)	0.160
BSA [m2]	1.8 (0.7–2.1)		1.5 (0.7–2.2)	0.173
Female (%)	14 (45%)		14 (48%)	1
Diagnosis				0.001
TOF	15 (47%)		15 (50%)	
TOF/pulmonary atresia	9 (28%)		1 (3%)	
DORV, dTGA, TAC	3 (9%)		1 (3%)	
Aortic valve disease	4 (13%)		0 (0%)	
Pulmonary valve stenosis or atresia	0 (0%)		13 (43%)	
Prior RVOT surgeries				<0.001
Homograft	11 (34%)		0 (0%)	
Bioprosthetic valve	12 (38%)		1 (3%)	
Transannular patch	8 (25%)		23 (77%)	
Rev or valvectomy	1 (3%)		5 (17%)	
Balloon angioplasty	0 (0%)		1 (3%)	
Indication for PVR				<0.001
RVOTO	10 (31)		0 (0%)	
PI	9 (28%)		27 (90%)	
Combined RVOTO/PI	13 (41%)		3 (10%)	
Time since PVR at last follow-up [days]	745 (212–1397)		697 (222–1482)	0.618

Data are presented as median (range) or number (percent) as appropriate. Abbreviations: PVR (pulmonary valve replacement), TOF (Tetralogy of Fallot), DORV (double outlet right ventricle), dTGA (D-transposition of the great arteries), TAC (truncus arteriosus communis), RVOTO (right ventricular outflow tract obstruction), PI (pulmonary valve insufficiency).

Table 2

Echocardiographic characteristics of right ventricular outflow tract (RVOT) physiology and estimated right ventricular pressure at three different time points: 1. before trans-catheter Melody or surgical pulmonary valve replacement (pre PVR), 2. at the time of the first post-procedural echocardiogram (post PVR), and at most recent follow-up (last follow-up).

	Transcatheter PVR (n=32)				Surgical PVR (n=30)			
	Pre PVR	Post PVR	Last follow-up	P (time)	Pre PVR	Post PVR	Last follow-up	P (time)
Moderate-severe RVOT obstruction [n(%)]	23 (74%)**	7 (22%)	2 (6%)**	<0.001	3 (10%)	3 (10%)	12 (41%)	<0.001
Max. gradient [mmHg]	52 (26)	27 (12)*	22 (9)**	<0.001	20 (17)	22 (8)	33 (11)	<0.001
Moderate-severe pulmonary insufficiency [n(%)]	22 (69%)**	0 (0%)	0 (0%)**	<0.001	30 (100%)	0 (0%)	7 (24%)	<0.001
Moderate-severe RVOT obstruction and/or pulmonary insufficiency	32 (100%)	7 (22%)	3 (9%)**	<0.001	30 (100%)	3 (10%)	16 (53%)	<0.001
RVOT antegrade diastolic flow [n(%)]	13 (42%)	3 (10%)	0 (0%)*	<0.001	15 (52%)	0 (0%)	4 (14%)	<0.001
TR degree > mild [n(%)]	6 (21%)	4 (13%)	0 (0%)	0.031	5 (17%)	3 (10%)	2 (7%)	0.444
TRIG [mmHg]	49 (25)**	39 (19)	31 (9)	0.004	30 (14)	31 (12)	35 (10)	0.364

Data are presented as mean (standard deviation) or number (%) as appropriate. Comparisons between groups:

* p<0.05,
** p<0.01, p (time): within group time effect.

Abbreviations: PVR (pulmonary valve replacement), TR (tricuspid regurgitation), TRIG (TR jet gradient).

Table 3
Function of the transcatheter Melody vs surgical pulmonary valve by age (A: <17 years, B: ≥17 years of age at time of PVR).

A: Age <17 years			
	Transcatheter PVR (n=10)	Surgical PVR (n=17)	p
Follow-up [days]	755 (391)	956 (360)	0.187
At least moderate PS	1 (10%)	11 (65%)	0.007
At least moderate PI	0 (0%)	8 (47%)	0.011
PVR dysfunction (PS and/or PI)	1 (10%)	14 (82%)	<0.001
B: Age ≥17 years			
	Transcatheter PVR (n=22)	Surgical PVR (n=13)	p
Follow-up [days]	836 (343)	570 (235)	0.011
At least moderate PS	2 (9%)	2 (15%)	0.478
At least moderate PI	0 (0%)	0 (0%)	N/A
PVR dysfunction (PS and/or PI)	2 (9%)	2 (15%)	0.478

Abbreviations: PVR (pulmonary valve replacement), PS (pulmonary valve stenosis), PI (pulmonary valve insufficiency).

Echocardiographic characteristics of right heart size and function in the trans-catheter vs surgical PVR groups at three different time points: 1. before trans-catheter Melody or surgical pulmonary valve replacement, 2. at the time of the first post-procedural echocardiogram, and at most recent follow-up.

Table 4

Time point:	Transcatheter PVR (n=32)				Surgical PVR (n=30)			
	Pre PVR	Post PVR	Last follow-up	P (time)	Pre PVR	Post PVR	Last follow-up	P (time)
Right Atrial Structure								
Major dimension [cm]	4.7 (0.1)	5.3 (0.7)	4.4 (0.2)	13**	5.1 (0.2)	5.1 (1.3)	4.8 (0.2)	13**
Minor dimension [cm]	4.3 (0.1)	4.1 (0.2)	3.9 (0.1)	12* 13**	4.6 (0.2)	4.5 (0.2)	4.3 (0.2)	13**
Area in end-systole [cm ²]	18.4 (1)*	17.5 (1)	15.9 (1)	13* 23*	22.4 (1.4)*	18.9 (1.4)	10 (1.4)	12** 13**
Right Ventricular Structure								
Basal dimension [cm]	4.4 (0.2)**	4.2 (0.2)	4.2 (0.2)	NS	5.2 (0.2)**	4.4 (0.2)	4.2 (0.2)	12** 13**
Mid-ventricular dimension [cm]	3.7 (0.1)*	3.3 (0.1)	3.2 (0.1)	12** 13**	4.3 (0.2)*	3.3 (0.2)	3.2 (0.2)	12** 13**
End-diastolic area [cm ²]	30.1 (1.6)*	26.1 (1.6)	26.6 (1.4)	12** 13**	37 (2.3)*	26.4 (2.3)	24.7 (2.1)	12** 13**
End-systolic area [cm ²]	16.7 (1.1)	14.8 (1)	14.9 (1.0)	NS	19.6 (1.4)	16.5 (1.4)	14.2 (1.4)	12** 23* 13**
RVOT proximal [cm]	2.4 (0.1)	2.3 (0.1)	2.2 (0.1)*	NS	2.6 (0.2)	2.5 (0.1)	2.7 (0.1)*	NS
RVOT distal [cm]	2.1 (0.1)*	2.2 (0.1)	2.1 (0.1)	NS	2.4 (0.1)*	2.3 (0.1)	2.3 (0.1)	NS
Free wall thickness [mm]	5.5 (0.2)	5.5 (0.2)	5.1 (0.2)	23*	5.5 (0.3)	5.6 (0.3)	5.4 (0.3)	NS
Right Ventricular Function								
RV fractional area change [%]	43.6 (2.2)	42 (1.9)	44.5 (2.3)	NS	48.4 (2.9)	39.3 (2.7)	44.2 (3)	12** 23*
TAPSE [cm]	1.5 (0.1)	1.5 (0.1)*	1.5 (0.1)	NS	1.7 (0.1)	1.2 (0.1)*	1.4 (0.1)	12** 23* 13**

Time point:	Transcatheter PVR (n=32)				Surgical PVR (n=30)			
	Pre PVR	Post PVR	Last follow-up	P (time)	Pre PVR	Post PVR	Last follow-up	P (time)
TDI RV S' [cm/s]	7.4 (0.5) ^{**}	8 (0.4)	7.1 (0.3)	23 [*]	9.3 (0.6) ^{**}	7.4 (0.6)	7.1 (0.5)	12 ^{**} 13 ^{**}

Data are derived from a mixed linear model correcting for PVR indication (PS, PI or PS/PI), BSA, and age at intervention. Data are presented as estimate (standard error). Comparisons between groups:

^{*} p<0.05,

^{**} p<0.01, p (time): within group time effect between time points 1, 2, and 3.

Abbreviations: PVR (pulmonary valve replacement), RVOT (right ventricular outflow tract), TAPSE (tricuspid annular plane systolic excursion), TDI RV S' (velocity of the tricuspid annular systolic motion).